Tyra Biosciences, Inc. Form 8-K Summary
Business Context and Reporting Period
Tyra Biosciences, Inc. (TYRA), a Delaware corporation, filed this Current Report on Form 8-K on September 14, 2026. The filing discloses the entry into an underwriting agreement for a public offering of common stock and pre-funded warrants.
Key Financial Metrics and Transaction Details
- Offering Size: 9,079,000 shares of Common Stock and 9,078,529 Pre-Funded Warrants.
- Offering Price: $22.03 per share of Common Stock; $22.029 per Pre-Funded Warrant.
- Underwriter Purchase Price: $20.7082 per share; $20.7072 per Pre-Funded Warrant.
- Gross Proceeds: Approximately $400.0 million (before underwriting discounts and offering expenses).
- Underwriters: Jefferies LLC, Guggenheim Securities, LLC, Cantor Fitzgerald & Co., and Barclays Capital Inc.
- Expected Closing Date: September 15, 2026.
Material Changes and Transaction Structure
The filing represents a material capital raise event. The Pre-Funded Warrants are immediately exercisable at $0.001 per share and do not expire. Beneficial ownership limitations apply, restricting exercise if a holder would own more than 4.99%, 9.99%, or 19.99% of outstanding shares (as selected by the holder), though holders may adjust this cap up to 19.99% with a 61-day notice period. The offering is conducted under a shelf registration statement (No. 333-298911).
Guidance, Outlook, and Risks
The Company issued a press release on September 14, 2026, announcing the pricing. The filing includes forward-looking statements regarding the expected closing and proceeds. Actual results may differ due to market conditions and customary closing conditions. Investors are directed to the "Risk Factors" in the Company's Form 10-K for the year ended December 31, 2025, for a discussion of inherent business risks. The filing does not provide updated revenue, profit, or cash flow metrics for the current period.
Investor Verification Checklist
- Verify the final closing of the offering on September 15, 2026, and the actual net proceeds after deducting underwriting discounts and expenses.
- Review the full text of the Underwriting Agreement (Exhibit 1.1) and Pre-Funded Warrant (Exhibit 4.1) for specific covenants and termination provisions.
- Assess the dilution impact of the 9,079,000 new shares and 9,078,529 pre-funded warrants on existing shareholders.
- Confirm the use of proceeds as detailed in the accompanying press release (Exhibit 99.1).